Targeting prostate cancer cells with enzalutamide‐HDAC inhibitor hybrid drug 2‐75-Reference-Cited by-同舟云学术

Targeting prostate cancer cells with enzalutamide‐HDAC inhibitor hybrid drug 2‐75

Published:2019-05-28 Issue:10 Volume:79 Page:1166-1179
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Hu Wen‐Yang¹,Xu Liping²,Chen Bailing²,Ou Siyu²,Muzzarelli Kendall M.³,Hu Dan‐Ping¹,Li Ye¹,Yang Zhe³,Vander Griend Donald J.⁴,Prins Gail S.¹,Qin Zhihui²^ORCID

Affiliation:

1. Department of Urology University of Illinois at Chicago Chicago Illinois

2. Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan

3. Department of Biochemistry and Molecular Biology Wayne State University School of Medicine Detroit Michigan

4. Department of Pathology University of Illinois at Chicago Chicago Illinois

Funder

Wayne State University

U.S. Department of Defense

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.23832

Reference54 articles.

1. American Cancer Society.Facts & Figures 2018. Atlanta Ga2018.

2. A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer

3. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

4. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

5. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the JAK1 /STAT3 Signaling Pathway: Entinostat as a Promising Treatment for Nasopharyngeal Carcinoma;2024-05-22

2. Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy;Cancer Cell International;2024-04-09

3. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer;International Journal of Oncology;2024-01-12

4. A novel GRK3-HDAC2 regulatory pathway is a key direct link between neuroendocrine differentiation and angiogenesis in prostate cancer progression;Cancer Letters;2023-09

5. Therapeutic applications of the prostate cancer epigenome;Epigenetic Cancer Therapy;2023